SCHEMBL3208941

SCHEMBL3208941

CC(C)(C)OC(=O)N1CCc2ccc(CO)cc21

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.52
CHRM4 P08173 1/20 0.52
HTR7 P34969 1/20 0.52
DHODH Q02127 1/20 0.46
ESR2 Q92731 1/20 0.45
NR1H2 P55055 1/20 0.44
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HTR2C P28335 1/20 0.42
NOTUM Q6P988 1/20 0.42
GPR119 Q8TDV5 7/20 0.41
MPO P05164 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM1A O60341 1/20 0.41
DRD4 P21917 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29888719 1.00 DRD2 (0.52) DRD2CHRM4HTR7DHODHESR2
SCHEMBL1466633 0.90 DHODH (0.56) DRD2CHRM4HTR7DHODHESR2
SCHEMBL11977137 0.87 DRD2 (0.50) DRD2CHRM4HTR7DHODHESR2
SCHEMBL11976686 0.85 DRD2 (0.48) DRD2CHRM4HTR7DHODHESR2
SCHEMBL24820902 0.83 CHRM4 (0.47) DRD2CHRM4HTR7DHODHESR2
SCHEMBL23063860 0.82 DRD2 (0.52) DRD2CHRM4HTR7ESR2NR1H2
SCHEMBL3905057 0.82 ESR2 (0.61) DRD2CHRM4HTR7DHODHESR2
SCHEMBL13267309 0.82 MPO (0.48) DRD2CHRM4HTR7DHODHESR2
SCHEMBL6297834 0.81 CHRM4 (0.51) DRD2CHRM4HTR7DHODHESR2
SCHEMBL595638 0.81 CHRM4 (0.51) DRD2CHRM4HTR7ESR2NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3262053-B1 IMIDAZOTHIADIAZOLE COMPOUNDS AS PAR4-INHIBITORS UNIV MONTREAL (CA) 2022-10-05 EP disclosed
US-20180237457-A1 IMIDAZOPYRIDAZINE AND IMIDAZOTHIADIAZOLE COMPOUNDS UNIVERSITE DE MONTREAL (CA) 2018-08-23 US disclosed
WO-2016134450-A1 IMIDAZOPYRIDAZINE AND IMIDAZOTHIADIAZOLE COMPOUNDS Université de Montréal (CA) 2016-09-01 WO disclosed
US-8962674-B2 Curcumin derivative TOKYO INSTITUTE OF TECHNOLOGY (JP) 2015-02-24 US disclosed
US-20100048901-A1 NOVEL CURCUMIN DERIVATIVE TOKYO INSTITUTE OF TECHNOLOGY (JP) 2010-02-25 US disclosed
EP-2123637-A1 NOVEL CURCUMIN DERIVATIVE Tokyo Institute of Technology (JP) 2009-11-25 EP disclosed
US-7071201-B2 Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline EISAI CO., LTD. (JP) 2006-07-04 US disclosed
CN-1204121-C 1,4-substituted cyclic amine derivatives EISAI CO LTD (JP) 2005-06-01 CN disclosed
EP-0976732-B1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES EISAI CO LTD (JP) 2004-11-24 EP disclosed
US-20030232860-A1 Medicine comprising dicyanopyridine derivative ASTELLAS PHARMA INC. (JP) 2003-12-18 US disclosed
US-6579881-B2 Indoles EISAI CO., LTD. (JP) 2003-06-17 US disclosed
EP-1302463-A1 MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-04-16 EP disclosed
US-6448243-B1 SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA EISAI CO., LTD. (JP) 2002-09-10 US disclosed
US-20020086999-A1 Certain quinoline derivatives EISAI CO., LTD. 2002-07-04 US disclosed
US-20020019531-A1 Indoles EISAI CO., LTD. 2002-02-14 US disclosed
CN-1253547-A 1,4-substituted cyclic amine derivatives EISAI CO LTD (JP) 2000-05-17 CN disclosed
EP-0976732-A1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048901-A1 NOVEL CURCUMIN DERIVATIVE BACE1, APP, BACE2 DRD2 981/4885CHRM4 2826/4885HTR7 1085/4885
US-20020019531-A1 Indoles INMT, MUSK, MB DRD2 51/4885CHRM4 167/4885HTR7 71/4885
US-20020086999-A1 Certain quinoline derivatives CHRM1, CHRNA5, CHRNA4 DRD2 54/4885CHRM4 42/4885HTR7 57/4885
US-20030232860-A1 Medicine comprising dicyanopyridine derivative KCNN3, KCNN2, KCNN1 DRD2 1145/4885CHRM4 361/4885HTR7 1372/4885
US-20180237457-A1 IMIDAZOPYRIDAZINE AND IMIDAZOTHIADIAZOLE COMPOUNDS F12, F2, F3 DRD2 2293/4885CHRM4 845/4885HTR7 2686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.